forzinity and elamipretide: One Molecule, Six Names
Disclaimer: All content on this site is based on public academic research and clinical data for educational and informational reference only. It is not medical advice. No treatment or health-related decisions should be made based solely on website content. This site does not sell pharmaceuticals or endorse any medical treatment.
The short answer: yes, the same molecule
forzinity and elamipretide are the same chemical entity. elamipretide is the generic (international nonproprietary) name; forzinity is the proprietary brand name carried on the September 2025 FDA approval. The molecule is the tetrapeptide D-Arg–2',6'-Dmt–Lys–Phe–NH2 documented on our structure page — and it carries four more names worth mapping precisely.
Why does the naming question deserve its own page? Because the search landscape is fragmented across all six names — academic readers know ss-31, clinical readers know elamipretide or forzinity, and the research-supply market knows 2S50 — so secondary sources routinely treat the same molecule as two or three different things. This page is the disambiguation layer for the entire site; the elamipretide pillar carries the molecule science, and the forzinity pillar the brand-level record.
The name map, with history
ss-31 is the oldest surviving name: sequence 31 from an academic screening library of cationic peptides, still the most common designation in the basic-science literature. MTP-131 and Bendavia are development-stage names from the molecule's clinical translation period. elamipretide became the formal generic name; forzinity the approved U.S. brand; 2S50 a research-catalog designation used by laboratory suppliers. Every name encodes a channel and an era — the table below is the full map.
The two names in this page's title are the pair that matters most for search: people who know “forzinity” from news coverage and people who know “elamipretide” from literature are looking at the same substance through different institutional lenses. The comparison questions that follow — forzinity vs ss-31 and forzinity vs 2S50 — are therefore channel comparisons, not molecule comparisons.
Why the names map to channels
The name a source uses predicts what it is selling or citing. “forzinity” belongs to the regulated channel: a prescription product with an FDA label, GMP manufacturing and specialty distribution. “ss-31 peptide” and “2S50” belong to the research channel: catalog material for laboratory use with certificates of analysis and no regulatory standing. “elamipretide” is jurisdiction-neutral and appears in both.
This mapping has legal weight. The regulated product is a prescription drug; the research material is a chemical reagent. Material from one channel is not a substitute for material from the other — a point quantified (purity, documentation, price, legality) on the comparison pages, and bounded by our disclaimer everywhere on this site. We do not guide anyone toward either channel; we document both.
How to cite the molecule correctly
Citation practice on this site: use elamipretide for the molecule generically, ss-31 when discussing pre-2020 basic literature, forzinity only for the approved product and its label data, and 2S50 only for the research-catalog designation. Mixing eras produces sentences that are chemically true and commercially misleading — the exact failure mode this page prevents.
For searchers, the practical rule is symmetric: when you read a page about “ss-31” making claims about a price in dollars per vial, or a page about “forzinity” citing research-grade purity data, you have found channel confusion wearing a name. Check which channel the document belongs to before citing it — the data-usage steps below operationalize the check.
How to use the data on this page
Step 1 — extract the parameters. Extract the name a source uses before extracting its claims: the six names map to specific channels and eras, and a claim about ‘ss-31’ from 2011 and one about ‘forzinity’ from 2025 are different evidentiary objects even when chemically identical.
Step 2 — normalize before comparing. Normalize by converting every name to the molecule level first (elamipretide), then re-attach exactly one channel label: regulated drug, academic literature, or research-grade catalog. Claims that cross channels silently should be flagged and downgraded.
Step 3 — grade the source. Grade the source with the name as a sorting key: regulatory documents use the brand or INN; peer-reviewed papers use the era-appropriate code name; marketing pages use whichever name ranks. The name a source chose is itself evidence of its tier.
Parameter comparison
The complete elamipretide name map, with era and channel for each designation.
| Name | Type | Era / context | Channel |
|---|---|---|---|
| ss-31 | Screening-library code name | Basic science literature, 2000s onward | Academic |
| MTP-131 | Development code name | Early clinical translation | Clinical development |
| Bendavia | Development brand name | Mid-stage clinical programs | Clinical development |
| elamipretide | Generic (INN) name | Formal nomenclature, current | All channels |
| forzinity | U.S. brand name | FDA approval, Sept 2025 onward | Regulated pharmaceutical |
| 2S50 | Research-catalog designation | Research-supply market | Laboratory reagent |
Table: The complete elamipretide name map, with era and channel for each designation. — compiled from public regulatory and academic sources; verify against the original documents before use.
Frequently asked questions
Is forzinity the same as elamipretide?
Yes — forzinity is the brand name and elamipretide the generic name of the same tetrapeptide, also known historically as ss-31, MTP-131 and Bendavia, and sold for laboratory research under the catalog designation 2S50.
Why does this peptide have so many names?
Each name marks a stage or channel: an academic screening code (ss-31), development code names (MTP-131, Bendavia), the formal generic name (elamipretide), the approved brand (forzinity), and a research-catalog designation (2S50). The molecule never changed — the institutions naming it did.
References
- FDA forzinity (elamipretide) prescribing information — naming and nomenclature sections.
- ss-31 and MTP-131 literature (PubMed indexed) for historical naming usage.
- Research-catalog records for the 2S50 designation (public supplier listings).